First human trial begins for experimental inhaled medication
NCT ID NCT07285122
Summary
This early-stage study aims to test the safety and tolerability of a new inhaled medication called RB042 in healthy adults, including smokers. Researchers will measure side effects and track how the drug moves through the body after single and multiple doses. The study involves 90 participants and is primarily focused on establishing basic safety information before testing in patients with specific conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.